Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.63 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.63 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002875 | 0.93 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1TRAP1ALDH1A1HPGD | |
| SCHEMBL1780605 | 0.88 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1TRAP1ALDH1A1HPGD | |
| SCHEMBL5471443 | 0.88 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL14582313 | 0.87 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1TRAP1ALDH1A1HPGD | |
| SCHEMBL14582312 | 0.86 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1TRAP1ALDH1A1HPGD | |
| SCHEMBL14582338 | 0.85 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1ALDH1A1HPGD | |
| SCHEMBL14582346 | 0.85 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1TRAP1HPGD | |
| SCHEMBL5459571 | 0.84 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1ALDH1A1HPGD | |
| SCHEMBL5464355 | 0.83 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL5464958 | 0.83 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | claimed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885TRAP1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.